6 completed, 1 not yet recruiting, 1 recruiting. 8 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 8 | Completed 6, Not yet recruiting 1, Recruiting 1 |
Follow Vivax Malaria: new trials by email Literature Review of Vivax Malaria trials Research Report on Vivax Malaria
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Tafenoquine and ACTs (TADORE- Plus) Tafenoquine plus DHA-Piperaquine, Tafenoquine plus Artesunate-pyronaridine - Vivax Malaria | Phase 4 | Not yet recruiting | Menzies School of Health Research | 507 | 2026-06-01 | 2026-03-18 |
| Primaquine for Vivax Malaria in G6PD Intermediate and Deficient Cases. Patients with G6PD enzyme activities between 30 and <70% of the AMM will be treated with schizontocidal treatment plus high dose primaquine 1mg/kg/day for 7 days, Patients with G6PD enzyme activities <30% of the AMM will be treated with schizontocidal treatment plus 8 weekly primaquine (0.75mg/kg dose). - Vivax Malaria, G6PD Deficiency | Phase 4 | Recruiting | Menzies School of Health Research | 100 | 2024-05-17 | 2026-03-12 |
| Therapeutic Efficacy of Chloroquine Plus Primaquine in the Treatment of Uncomplicated Plasmodium Vivax Chloroquine, Primaquine - Efficacy, Malaria | Phase 4 | Completed | Dinka Dugassa | 100 | 2022-12-19 | 2023-09-22 |
| Rigorous Assessment of P. Vivax Relapses and Primaquine Efficacy for Radical Cure Primaquine, Artesunate - Vivax Malaria | Phase 4 | Completed | University of Maryland, Baltimore | 160 | 2021-04-15 | 2026-06-03 |
| Reducing the Risk of P. Vivax After Falciparum Infections in Co-endemic Areas primaquine - Malaria, Vivax Malaria | Phase 4 | Completed | Menzies School of Health Research | 500 | 2019-08-18 | 2023-11-21 |
| G6PD Assessment Before Primaquine for Radical Treatment of Vivax Malaria Chloroquine, Primaquine 0.25 mg/kg/day, Primaquine 0.75 mg/kg weekly - Vivax Malaria | Phase 4 | Completed | University of Oxford | 1000 | 2016-09-01 | 2020-10-14 |
| Assessment of Plasmodium Vivax Chloroquine Resistance in Cambodia: Chloroquine sulfate, DHA-PP - Vivax Malaria | Phase 4 | Completed | Institut Pasteur, Cambodia | 73 | 2014-05-01 | 2015-03-24 |
| Estimating the Risk of Plasmodium Vivax Relapses in Afghanistan Chloroquine, Chloroquine/Primaquine - Vivax Malaria | Phase 4 | Completed | University of Oxford | 593 | 2009-08-01 | 2019-01-15 |
Malaria, Vivax (8) · Malaria (4) · Glucosephosphate Dehydrogenase Deficiency (1) · Malaria, Falciparum (1) · Recurrence (1)
Infections (8) · Mosquito-Borne Diseases (8) · Parasitic Diseases (8) · Protozoan Infections (8) · Vector Borne Diseases (8) · Malaria (4) · Anemia (1) · Anemia, Hemolytic (1) · Anemia, Hemolytic, Congenital (1) · Carbohydrate Metabolism, Inborn Errors (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Disease Attributes (1) · Genetic Diseases, Inborn (1) · Hematologic Diseases (1) · Hemic and Lymphatic Diseases (1)
Primaquine (6) · Chloroquine (4) · 2,6-diisopropylphenol docosahexaenoate (1) · Artesunate (1) · chloroquine diphosphate (1) · pyronaridine tetraphosphate, artesunate drug combination (1) · tafenoquine (1)
Menzies School of Health Research (3) · University of Oxford (2) · Dinka Dugassa (1) · Institut Pasteur, Cambodia (1) · University of Maryland, Baltimore (1)
Ethiopia (3) · Afghanistan (2) · Cambodia (2) · Bangladesh (1) · Brazil (1) · Indonesia (1) · Papua New Guinea (1)
Bockretsion Gidey (1) · Dysoley Lek, MD (1) · Ghulam Rahim Awab, MD (1) · Jean Popovici, PhD (1) · Kamala Thriemer, MD (1)
PMID 29362233, PMID 33299558, PMID 33552517, PMID 34336132, PMID 35585641, PMID 37979594, PMID 39802788, PMID 40112852, PMID 42439801
R01AI103228 (1)